Table 4. MDD diagnosis of patients undergoing TBCB.
MDD diagnosis | Case (%) |
---|---|
CTD-ILD | 89 (23.9) |
IPF | 33 (8.8) |
INSIP | 7 (1.9) |
COP | 7 (1.9) |
PAP | 15 (4.0) |
PAM | 10 (2.7) |
Lung cancer | 18 (4.8) |
Pneumonia | 11 (2.9) |
HP | 6 (1.6) |
Sarcoidosis | 5 (1.3) |
Pneumoconiosis | 5 (1.3) |
Desquamative interstitial pneumonia | 4 (1.1) |
TB | 4 (1.1) |
Emphysema | 4 (1.1) |
RB-ILD | 3 (0.8) |
ACFE | 2 (0.5) |
PCP | 1 (0.3) |
PLCH | 1 (0.3) |
PAM | 1 (0.3) |
Cryptococcosis | 1 (0.3) |
Occupational-related pneumonia | 1 (0.3) |
Radiation pneumonia | 1 (0.3) |
Diffuse large B lymphoma in pulmonary vessels | 1 (0.3) |
Giant cell interstitial pneumonia | 1 (0.3) |
Lipid pneumonia | 1 (0.3) |
IPH | 1 (0.3) |
PIE | 1 (0.3) |
PO | 1 (0.3) |
DR-ILD | 1 (0.3) |
Aspiration pneumonia | 1 (0.3) |
ND | 136 (36.5) |
MDD, multidisciplinary discussion; CTD, connective tissue disease; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; iNSIP, idiopathic non-specific interstitial pneumonia; ACFE, airway-centered fibroelastosis; COP, cryptogenic organizing pneumonia; PAP, pulmonary alveolar proteinosis; PLAM, pulmonary lymphangiomyomatosis; HP, hypersensitivity pneumonitis; DIP, desquamative interstitial pneumonia; PCP, pneumocystis pneumonia; PLCH, pulmonary Langerhans cell histiocytosis; RB-ILD, respiratory bronchiolitis-interstitial lung disease; TB, tuberculosis; PAM, pulmonary alveolar microlithiasis; PO, pulmonary ossification; IPH, idiopathic pulmonary hemosiderosis; DR-ILD, drug-related interstitial lung disease.